автор: Jagat R. Kanwar

Professor Bhupinder Singh Bhoop is globally acclaimed for his research on novel and nanostructured drug delivery using Quality by Design (Qb D) paradigms, he has contributed over three decades of dedicated service towards Pharmaceutical Education and Research. His work primarily focuses on lipidic nanostructured systems like SNEDDS (liquid, solid, supersaturable and eutectic), solid lipid nanoparticles (SLNs), nanostructured lipid carriers (NLCs), nanoemulsions and mixed nanomicelles, polymeric nanoparticles, functionalized CNTs, and nanovesicular systems like liposomes, niosomes, ethosomes, transfersomes and bilosomes. He has to his credit over 215 publications including 9 books and 33 book chapters. More than 225 keynotes and invited talks have been delivered by him at prestigious forums in various countries. He has organized several Conferences and Symposia including International Conferences, Nano Sci Tech 2012 & 2014. He has handled 15 research projects and guided/guiding 27 Ph D, 4 post-doctorates and over 50 postgraduate scholars. He has completed over a dozen consultancy assignments and industrial projects, has 4 patents and key involvement in tech. transfers of three nano-based drug delivery products. He has duly trained several hundreds of industrial scientists under his guidance esp. Qb D of nanostructured systems. His work has fetched him several awards and accolades like, Leading Educators of World (UK) 2007, Pharma Buzz Pharma Personality Award 2008, Shiksha Rattan Award 2008, Innovative Scientist Award 2012, Pharma Qb D Excellence Award 2012 by CPh I-Asia, Qb D Product Performance Award 2012 and 2013 by Amer Assoc Pharm Sci, USA, Outstanding Scientist Award 2014 by Select Biosciences, UK, PUTA Excellence Award 2014, and Stat Ease Qb D Performance Award 2014, USA. Currently, he is the Chairman of University Institute of Pharmaceutical Sciences, and the Coordinator of UGC Centre of Advanced Studies (CAS) in Pharmaceutical Sciences. Since 2011, he has also been serving as the Founder Coordinator of UGC Centre for Excellence in Nano Applications (Biomedical Sciences). Besides, he has also been the Dean, Faculty of Pharmaceutical Sciences, Panjab University, Chandigarh (2012-14) and Dean Alumni Relations, Panjab University (2007-2011). On the basis of his exemplary accomplishments, the Vice President of India has nominated him to the Senate of Panjab University as its Fellow. E-mail: [email protected], [email protected] Professor Jagat R Kanwar is the Head and team leader of Nanomedicine-Laboratory of Immunology and Molecular Biomedical Research (NLIMBR), School of Medicine, Faculty of Health, Deakin University, Australia. Dr Kanwar is an internationally reputed expert in investigating fundamental and applied molecular signalling aspects of pathogenesis of cancer, chronic inflammation and neurodegenerative diseases, leading thereby to the development of treatment strategies from bench to bedside. He has more than 110 publications in high impact factor peer-reviewed international journals, 27 book chapters and 3 edited books. Professor Kanwar’s research has generated several patents/PCTs, with more than five licensed patents resulting in commercialization by Bio Pharma industry. His group is currently working on drug discovery and nanomedicines for oral and systemic drug delivery of a range of biomacromolecules (proteins/peptides, si RNAs and aptamers) for targeting survivin, HIF-1a and other apoptotic and inflammatory cell signalling molecules in cancer, chronic inflammation and neurodegenerative disorders. His research combines immunology with cutting-edge techniques in molecular biology, biochemistry, nanobiotechnology and visualization to investigate the pathways through which key molecules are regulated in both normal and disease states. A number of in vitro human cell/tissue based co-culture models for cancers, microbial infections; autoimmune diseases; chronic inflammatory diseases (osteoarthritis, inflammatory bowel disease), gut health, neurodegeneration and immunomodulation have been developed by his group. Kanwar’s main research objective is to understand and target the mechanisms involved at the molecular and sub-cellular level which provides an edge over the prevalent targeting techniques. He carries out both academic and commercial research projects and develops new approaches for the diagnosis, treatment, and nanomedicine based new generation delivery systems. His recent research focuses on locked nucleic acid (LNA) modified aptamers conjugated “double targeted nano-bullet nanocapsules” with anti-tumour molecules to target the cancer cells as well as cancer stem cells specifically. E-mail: [email protected]